Endo, Inc. (OTCQX: NDOI) announced today that a post hoc data analysis of a Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum, or CCH) in patients with Peyronie's disease (PD) ...
Endo, Inc. (OTCQX: NDOI) ("Endo" or the "Company") announced today that it has rescheduled the release of its fourth quarter and full year 2024 financial results to March 13, 2025, prior to market ...
More than a decade after earning FDA approval for Xiaflex as a nonsurgical treatment option for Dupuytren’s contracture, Endo is debuting its first-ever branded TV commercial in the indication.
Campaign builds on the momentum of Endo's disease awareness efforts.Commercial features a real patient—who was an untreated patient in a prior Endo video series—and his wife, ...